{"transactions":[{"id":744677,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-09T21:40:32.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting."}],"balance_after":13000,"derivative":{"exercise_price":51.84,"expiration_date":"2036-06-05","underlying":"Common Shares","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001193125-26-264279","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000119312526264279/ownership.xml","form_type":"4"}},{"id":1071392,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-08-08T20:06:28.000Z","date":"2025-08-06","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":57.03,"value":1140600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Open market purchase of shares in accordance with Issuer's trading policies."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.92 to $57.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":22000,"source":{"system":"sec-edgar","filing":"0001688192-25-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000168819225000004/ownership.xml","form_type":"4"}},{"id":1092433,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T19:03:04.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option."}],"balance_after":0,"derivative":{"exercise_price":1.06,"expiration_date":"2035-03-10","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-25-094091","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025094091/ownership.xml","form_type":"4"}},{"id":1092432,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T19:03:04.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":86979,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option."}],"balance_after":0,"derivative":{"exercise_price":2.77,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":86979},"source":{"system":"sec-edgar","filing":"0000950170-25-094091","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025094091/ownership.xml","form_type":"4"}},{"id":1092431,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman"}}],"security":"Restricted Stock Units","published_at":"2025-07-03T19:03:04.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000950170-25-094091","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025094091/ownership.xml","form_type":"4"}},{"id":1092430,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman"}}],"security":"Common Stock","published_at":"2025-07-03T19:03:04.000Z","date":"2025-07-01","kind":"other","planned":false,"acquired":false,"shares":43861,"price":4,"value":175444.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-094091","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025094091/ownership.xml","form_type":"4"}},{"id":1100252,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman"}}],"security":"Common Stock","published_at":"2025-06-27T16:05:09.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":2815,"price":0.74,"value":2083.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period."}],"balance_after":43861,"source":{"system":"sec-edgar","filing":"0000950170-25-090864","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025090864/ownership.xml","form_type":"4"}},{"id":1119681,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:30:26.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders."}],"balance_after":13000,"derivative":{"exercise_price":38.57,"expiration_date":"2035-06-05","underlying":"Common Shares","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0000950170-25-083273","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000095017025083273/ownership.xml","form_type":"4"}},{"id":1179646,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman"}}],"security":"Restricted Stock Units","published_at":"2025-04-03T16:27:09.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On April 1, 2023, the reporting person was granted 100,000 RSUs. Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On April 1, 2023, the reporting person was granted 100,000 RSUs. Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-25-050443","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025050443/ownership.xml","form_type":"4"}},{"id":1179645,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman"}}],"security":"Common Stock","published_at":"2025-04-03T16:27:09.000Z","date":"2025-04-02","kind":"sale","planned":false,"acquired":false,"shares":8819,"price":0.89,"value":7848.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a durable automatic sale instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the reporting person."}],"balance_after":41046,"source":{"system":"sec-edgar","filing":"0000950170-25-050443","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025050443/ownership.xml","form_type":"4"}},{"id":1179644,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman"}}],"security":"Common Stock","published_at":"2025-04-03T16:27:09.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,490 shares of common stock acquired under the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan on March 31, 2025."}],"balance_after":49865,"source":{"system":"sec-edgar","filing":"0000950170-25-050443","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025050443/ownership.xml","form_type":"4"}},{"id":1203774,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2025-03-17T16:24:07.000Z","date":"2025-03-11","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-040314","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025040314/ownership.xml","form_type":"4"}},{"id":1203773,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-17T16:24:07.000Z","date":"2025-03-11","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price represents the closing price of the Issuer's common stock on March 11, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on March 11, 2025 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":400000,"derivative":{"exercise_price":1.06,"expiration_date":"2035-03-10","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-25-040314","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025040314/ownership.xml","form_type":"4"}},{"id":1392086,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-10-03T20:58:34.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":1710,"price":4.45,"value":7609.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP purchase period of April 1, 2024 through September 30, 2024. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on September 30, 2024, the last trading day of the purchase period."}],"balance_after":22375,"source":{"system":"sec-edgar","filing":"0000950170-24-112695","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024112695/ownership.xml","form_type":"4"}},{"id":1496702,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T20:15:03.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 30, 2024 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on May 31, 2024; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2025 Annual General Meeting of Shareholders."}],"balance_after":13000,"derivative":{"exercise_price":54.06,"expiration_date":"2034-05-30","underlying":"Common Shares","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0000950170-24-067323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000095017024067323/ownership.xml","form_type":"4"}},{"id":1549720,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2024-04-03T17:23:07.000Z","date":"2024-04-01","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On April 1, 2023, the reporting person was granted 100,000 RSUs. Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On April 1, 2023, the reporting person was granted 100,000 RSUs. Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-041301","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024041301/ownership.xml","form_type":"4"}},{"id":1549719,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-04-03T17:23:07.000Z","date":"2024-04-02","kind":"sale","planned":false,"acquired":false,"shares":7523,"price":6.94,"value":52209.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction was effected pursuant to a durable automatic sale instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.88 to $7.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":20665,"source":{"system":"sec-edgar","filing":"0000950170-24-041301","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024041301/ownership.xml","form_type":"4"}},{"id":1549718,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-04-03T17:23:07.000Z","date":"2024-04-01","kind":"exercise","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,188 shares of common stock acquired under the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan on March 28, 2024."}],"balance_after":28188,"source":{"system":"sec-edgar","filing":"0000950170-24-041301","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024041301/ownership.xml","form_type":"4"}},{"id":1574792,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-15T08:30:08.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on March 13, 2024 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":300000,"derivative":{"exercise_price":5.77,"expiration_date":"2034-03-12","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000950170-24-031877","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024031877/ownership.xml","form_type":"4"}},{"id":1860565,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T21:36:40.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 8, 2023 with respect to 13,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2023; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2024 Annual General Meeting of Shareholders."}],"balance_after":13000,"derivative":{"exercise_price":62.59,"expiration_date":"2033-06-08","underlying":"Common Shares","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001209191-23-035980","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000120919123035980/doc4.xml","form_type":"4"}},{"id":1928304,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted stock units","published_at":"2023-04-04T16:05:08.000Z","date":"2023-04-01","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock units were granted on April 1, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.  The restricted stock units vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on April 1, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.  The restricted stock units vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on April 1, 2023. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.  The restricted stock units vest in equal annual installments on each anniversary of the grant date until the fourth anniversary of the grant date."}],"balance_after":100000,"derivative":{"underlying":"Common stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-022649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919123022649/doc4.xml","form_type":"4"}},{"id":1928303,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock option (right to buy)","published_at":"2023-04-04T16:05:08.000Z","date":"2023-04-01","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price represents the closing price of the Issuer's common stock on March 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on April 1, 2023 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":800000,"derivative":{"exercise_price":5.73,"expiration_date":"2033-03-31","underlying":"Common stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001209191-23-022649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919123022649/doc4.xml","form_type":"4"}},{"id":2232707,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-14T07:52:26.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":9367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 10, 2022. The shares underlying the option are scheduled to vest as to 100% of the shares on June 10, 2023, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date."}],"balance_after":9367,"derivative":{"exercise_price":4.38,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":9367},"source":{"system":"sec-edgar","filing":"0001209191-22-036570","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919122036570/doc4.xml","form_type":"4"}},{"id":2236030,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T21:44:46.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders."}],"balance_after":12000,"derivative":{"exercise_price":71.7,"expiration_date":"2032-06-09","underlying":"Common Shares","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-22-036053","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000120919122036053/doc4.xml","form_type":"4"}},{"id":2655879,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-24T16:16:03.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":9367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 23, 2021. The shares underlying the option are scheduled to vest as to 100% of the shares on June 23, 2022, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date."}],"balance_after":9367,"derivative":{"exercise_price":17.12,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":9367},"source":{"system":"sec-edgar","filing":"0001209191-21-043009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919121043009/doc4.xml","form_type":"4"}},{"id":2670226,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-14T21:39:59.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 10, 2021 with respect to 10,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2021; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2022 Annual General Meeting of Shareholders."}],"balance_after":10000,"derivative":{"exercise_price":123.71,"expiration_date":"2031-06-10","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-040297","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000120919121040297/doc4.xml","form_type":"4"}},{"id":3076262,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-24T16:50:45.000Z","date":"2020-07-23","kind":"grant","acquired":true,"shares":9367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on July 23, 2020. The shares underlying the option are scheduled to vest as to 100% of the shares on July 23, 2021, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date."}],"balance_after":9367,"derivative":{"exercise_price":16,"expiration_date":"2030-07-22","underlying":"Common Stock","underlying_shares":9367},"source":{"system":"sec-edgar","filing":"0000899243-20-020402","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000089924320020402/doc4.xml","form_type":"4"}},{"id":3110596,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-15T20:45:32.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2020 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments."}],"balance_after":30000,"derivative":{"exercise_price":59.7,"expiration_date":"2030-06-11","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-036641","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000120919120036641/doc4.xml","form_type":"4"}},{"id":3183433,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-04-03T13:02:48.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":20833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit."},{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20833},"source":{"system":"sec-edgar","filing":"0001104659-20-042773","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465920042773/a4.xml","form_type":"4"}},{"id":3183432,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T13:02:48.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":311000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":21,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":311000},"source":{"system":"sec-edgar","filing":"0001104659-20-042773","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465920042773/a4.xml","form_type":"4"}},{"id":3183431,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T13:02:48.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":7.33,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001104659-20-042773","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465920042773/a4.xml","form_type":"4"}},{"id":3183430,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T13:02:48.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001104659-20-042773","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465920042773/a4.xml","form_type":"4"}},{"id":3183429,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T13:02:48.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":164285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":5.6,"expiration_date":"2026-08-16","underlying":"Common Stock","underlying_shares":164285},"source":{"system":"sec-edgar","filing":"0001104659-20-042773","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465920042773/a4.xml","form_type":"4"}},{"id":3183428,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T13:02:48.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":241460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":2.87,"expiration_date":"2025-12-10","underlying":"Common Stock","underlying_shares":241460},"source":{"system":"sec-edgar","filing":"0001104659-20-042773","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465920042773/a4.xml","form_type":"4"}},{"id":3183427,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T13:02:48.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":139371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":2.87,"expiration_date":"2025-12-10","underlying":"Common Stock","underlying_shares":139371},"source":{"system":"sec-edgar","filing":"0001104659-20-042773","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465920042773/a4.xml","form_type":"4"}},{"id":3183426,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-03T13:02:48.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":234707,"price":48,"value":11265936.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes (i) 377 shares of Issuer common stock acquired under the Issuer's Employee Stock Purchase Plan on December 10, 2019 and (ii) 14,620 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-042773","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465920042773/a4.xml","form_type":"4"}},{"id":3674464,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2019-02-06T00:38:16.000Z","date":"2019-02-01","kind":"exercise","acquired":false,"shares":20834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 1, 2018, the reporting person was granted 62,500 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":41666,"derivative":{"underlying":"Common Stock","underlying_shares":20834},"source":{"system":"sec-edgar","filing":"0001104659-19-005904","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465919005904/a4.xml","form_type":"4"}},{"id":3674463,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Options to Purchase Common Stock","published_at":"2019-02-06T00:38:16.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":311000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options vest in 48 equal monthly installments on each monthly anniversary following February 1, 2019, the grant date."}],"balance_after":311000,"derivative":{"exercise_price":21,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":311000},"source":{"system":"sec-edgar","filing":"0001104659-19-005904","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465919005904/a4.xml","form_type":"4"}},{"id":3674462,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"COMMON STOCK","published_at":"2019-02-06T00:38:16.000Z","date":"2019-02-01","kind":"tax_withholding","acquired":false,"shares":6327,"price":21,"value":132867.0,"ownership":{"direct":true},"balance_after":218799,"source":{"system":"sec-edgar","filing":"0001104659-19-005904","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465919005904/a4.xml","form_type":"4"}},{"id":3674461,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"COMMON STOCK","published_at":"2019-02-06T00:38:16.000Z","date":"2019-02-01","kind":"exercise","acquired":true,"shares":20834,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":225126,"source":{"system":"sec-edgar","filing":"0001104659-19-005904","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465919005904/a4.xml","form_type":"4"}},{"id":4076495,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2018-02-06T02:45:59.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These RSUs vest in three equal installments on each of February 1, 2019, February 1, 2020, and February 1, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not applicable."}],"balance_after":62500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001104659-18-006633","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465918006633/a4.xml","form_type":"4"}},{"id":4076494,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Options to Purchase Common Stock","published_at":"2018-02-06T02:45:59.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in 48 equal monthly installments on each monthly anniversary thereafter following February 1, 2018, the grant date."}],"balance_after":125000,"derivative":{"exercise_price":7.33,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001104659-18-006633","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465918006633/a4.xml","form_type":"4"}},{"id":4468818,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":40063,"kind":"person","name":"Treco Douglas A","position":1,"cik":"0001688192","reported_name":"Treco Douglas A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Options to Purchase Common Stock","published_at":"2017-02-03T21:28:03.000Z","date":"2017-02-01","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in 48 equal monthly installments at the end of each month following February 1, 2017, the grant date."}],"balance_after":225000,"derivative":{"exercise_price":16.64,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001104659-17-006443","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1688192/000110465917006443/a4.xml","form_type":"4"}}]}